Francisco Diaz-Mitoma

VBI Vaccines · Variation Biotechnologies Inc. · Novartis Vaccines

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers

PubMed author-name match

Trials

Studies that name Francisco Diaz-Mitoma as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:15 UTC. Open this list on ClinicalTrials.gov

Ph3
NCT03408730 · Lot-to-lot Consistency of Sci-B-Vac™ in Adults
VBI Vaccines Inc. · completed · Hepatitis B Vaccines · study director
Ph3
NCT03393754 · Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults
VBI Vaccines Inc. · completed · Hepatitis B Vaccines · study director
Ph1/Ph2
NCT03382977 · Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
VBI Vaccines Inc. · terminated · Glioblastoma Multiforme · study director
Ph2
NCT00310856 · Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)
Novartis Vaccines · completed · Meningococcal Meningitis · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:15 UTC. The ranking covers the 200 most relevant of 34 PubMed records, and a shared surname and initials can bring in a namesake. All 34 on PubMed

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.
Lancet Oncol · 2015
242 citations
RCR 9.2
Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group.
JAMA · 1996
123 citations
RCR 4.9
Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir.
J Infect Dis · 1998
117 citations
RCR 2.6
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
Vaccine · 2012
107 citations
RCR 3.0
Safe use of the CXCR4 inhibitor ALX40-4C in humans.
AIDS Res Hum Retroviruses · 2001
104 citations
RCR 2.1
Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group.
JAMA · 1998
97 citations
RCR 3.2
Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial.
Clin Infect Dis · 2006
74 citations
RCR 2.5
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.
Lancet Infect Dis · 2021
58 citations
RCR 3.9
Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults.
J Med Virol · 2001
55 citations
RCR 1.6
Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial.
JAMA Netw Open · 2021
54 citations
RCR 3.4